Legal & General Group
VRDN icon

Legal & General Group’s Viridian Therapeutics VRDN Stock Holding History

Legal & General Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
64,788
+5,163
+9% +$83.2K ﹤0.01% 2134
2026
Q1 		$1.17M Sell
59,625
-7,433
-11% -$221K ﹤0.01% 2093
2025
Q4 		$2.09M Buy
67,058
+7,075
+12% +$194K ﹤0.01% 1951
2025
Q3 		$1.29M Hold
59,983
– – ﹤0.01% 2167
2025
Q2 		$839K Sell
59,983
-232
-0.4% -$3.15K ﹤0.01% 2289
2025
Q1 		$812K Buy
60,215
+13
+0% +$221 ﹤0.01% 2251
2024
Q4 		$1.15M Buy
60,202
+11,133
+23% +$242K ﹤0.01% 2190
2024
Q3 		$1.12M Buy
49,069
+7,536
+18% +$123K ﹤0.01% 2196
2024
Q2 		$540K Buy
41,533
+2,446
+6% +$33.9K ﹤0.01% 2398
2024
Q1 		$684K Buy
39,087
+4,521
+13% +$87.6K ﹤0.01% 2317
2023
Q4 		$753K Buy
34,566
+7,206
+26% +$114K ﹤0.01% 2307
2023
Q3 		$420K Sell
27,360
-330
-1% -$6.29K ﹤0.01% 2499
2023
Q2 		$659K Buy
27,690
+11,727
+73% +$301K ﹤0.01% 2364
2023
Q1 		$406K Buy
15,963
+3,810
+31% +$122K ﹤0.01% 2378
2022
Q4 		$355K Buy
12,153
+1,950
+19% +$44.9K ﹤0.01% 2419
2022
Q3 		$209K Buy
10,203
+2,099
+26% +$37.7K ﹤0.01% 2613
2022
Q2 		$94K Buy
+8,104
New +$109K ﹤0.01% 2874
2019
Q3 		– Sell
-255
Closed -$8K – 3411
2019
Q2 		$8K Hold
255
– – ﹤0.01% 3398
2019
Q1 		$11K Hold
255
– – ﹤0.01% 3239
2018
Q4 		$12K Hold
255
– – ﹤0.01% 3236
2018
Q3 		$21K Hold
255
– – ﹤0.01% 3187
2018
Q2 		$25K Buy
255
+46
+22% +$4.86K ﹤0.01% 3099
2018
Q1 		$22K Buy
209
+87
+71% +$9.45K ﹤0.01% 3087
2017
Q4 		$19K Hold
122
– – ﹤0.01% 3153
2017
Q3 		$17K Hold
122
– – ﹤0.01% 3208
2017
Q2 		$24K Buy
+122
New +$20.6K ﹤0.01% 3119

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Legal & General Group's VRDN Position: Q2 2026 in Review

Legal & General Group increased its Viridian Therapeutics (VRDN) stake by 8.7% in Q2 2026, buying an estimated $83.2K and bringing the position to 64,788 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

Legal & General Group first reported a position in VRDN in Q2 2017 and has held it in 26 quarters since. The position peaked at $2.09M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Legal & General Group held 64,788 shares of Viridian Therapeutics worth $1.19M as of Q2 2026.
  • Legal & General Group bought 5,163 Viridian Therapeutics shares in Q2 2026, an estimated $83.2K.
  • Viridian Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2134 holding.
  • Legal & General Group first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 26 quarters since.
  • Legal & General Group's Viridian Therapeutics position peaked at $2.09M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.